Kryxana contains Ribociclib, an oral anticancer medicine used to treat hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer in combination with hormonal therapy. It belongs to the class of CDK4/6 inhibitors and helps slow the growth of cancer cells.

Mechanism of action:
Ribociclib blocks cyclin-dependent kinases 4 and 6 (CDK4/6), which are enzymes that cancer cells need to progress through the cell cycle and divide. By inhibiting these kinases, Kryxana prevents cancer cells from multiplying, slowing tumor growth.

Uses:

• Advanced or metastatic HR+, HER2-negative breast cancer in adults

• Used in combination with aromatase inhibitors or fulvestrant

• Helps delay disease progression and improve outcomes when used with hormone therapy

Adverse effects:
Common side effects include low blood cell counts (neutropenia, anemia, thrombocytopenia), fatigue, nausea, diarrhea, hair thinning, and mouth sores. Serious but less common effects include liver function abnormalities, infections due to immune suppression, and rare heart rhythm changes.